Table 2 Summary of patient-level characteristics
From: Growth pattern trajectories in boys with Duchenne muscular dystrophy
All participants (N = 598, M = 2604) | |
|---|---|
Age (years, mean ± sd) | 8.0 ± 1.8 |
Age range | 5–12.0 |
Duration of follow-up (years, mean ± sd) | 2.5 ± 1.9 |
GC (n (%)) | |
GC naïve | 58 (10%) |
GC started | 540 (90%) |
Prednisolone | 373 (62%) |
Daily | 202 (34%) |
Intermittent | 171 (29%) |
Deflazacort | 167 (28%) |
Daily | 121 (20%) |
Intermittent | 46 (8%) |
Deletion group (n (%)) | |
Group 1 | 210 (35%) |
Group 2 | 157 (26%) |
Group 3 | 22 (4%) |
Exon skipping amenable (n (%)) | |
Skip 8 | 12 (2%) |
Skip 44 | 47 (8%) |
Skip 45 | 60 (10%) |
Skip 51 | 68 (11%) |
Skip 53 | 46 (8%) |
NSAA score (mean ± sd) | 21.7 ± 7.7 |
NSAA range | 0–34 |
GC start age (mean ± sd) | 5.8 ± 1.5 |
Prednisolone Daily | 5.8 ± 1.5 |
Prednisolone Intermittent | 5.9 ± 1.5 |
Deflazacort Daily | 5.6 ± 1.5 |
Deflazacort Intermittent | 6.0 ± 1.6 |